Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Ether molecular structure

    Ether Stats & Data

    Sweet vitriol diethyl-ether Diethyl ether
    PubChem
    MW74.12
    FormulaC4H10O
    LogP0.9
    IUPACethoxyethane
    SMILESCCOCC
    InChIKeyRTZKZFJDLAIYFH-UHFFFAOYSA-N
    Chemical Class Dialkyl ether
    Psychoactive Class Depressant / Dissociative

    Pharmacology

    DrugBank

    Mechanism of Action

    The mechanism of action by which .... ethyl ether produce/s/ reversible loss of consciousness is still unclear. Anesthesia can be produced by a wide variety of chemical agents, ranging from inert rare gases to steriodal molecules. This apparent lack of specificity, together with the observation that general anesthesia can be reversed by high pressure, poses a unique pharmacological problem. Most theories concern interaction of anesthetics with either membrane lipids or hydrophobic regions of sp

    Metabolism

    It has been estimated that about 8-10% of absorbed ethyl ether is metabolized in the body whereas the remainder is excreted unchanged through the lungs. Ethyl ether is metabolized to ethanol and acetaldehyde by the inducible hepatic microsomal enzyme system, a cytochrome P450-containing monooxygenase system. Ethanol and acetaldehyde are rapidly oxidized to acetate, and the acetate subsequently enters the 2-carbon pool of intermediary metabolism.

    This section covers risks general risks for both medical and nonmedical inhalants. For specific risks with nonmedical inhalants, see Toxicity and harm potential for toxic inhalants It is strongly recommended that one use harm reduction practices when using this class of substances. Both medical and nonmedical inhalants should be avoided by:

    LD50

    • LD50: 996 mg/kg (Intravenous, Mouse) (L1327)
    • LD50: 2420 mg/kg (Intraperitoneal, Mouse) (L1327)
    • LD50: 1213 mg/kg (Oral, Rat) (A681)

    Carcinogenicity

    No indication of carcinogenicity to humans (not listed by IARC).

    Addiction & dependence

    The chronic use of many inhalants can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

    Effect Profile

    Curated + 54 Reports
    Dissociative 1.6

    Low dissociative depth with strong mania, low motor impairment

    Dissociative Depth×3
    12.5
    Mania / Compulsion×1
    101.2
    Insight / Novel Thought×2
    0
    Motor / Sensory Impairment×1
    23.1
    Catalog Erowid
    Based on reports from:

    Tolerance & Pharmacokinetics

    drugs.wiki

    No tolerance chart. Our decay curves for these drugs were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.

    How fast tolerance to these drugs fades after a break has not been measured well enough to draw, so don't count on a dose you used to take still being safe: after time off, start with a much smaller amount and don't use alone. Mixing sedatives with each other, with alcohol or with opioids sharply raises the risk of a fatal overdose. If you've been using regularly, don't stop suddenly: withdrawal from benzodiazepines, alcohol or GHB/GBL can cause seizures or delirium, so get medical help to cut down gradually.

    Sources: FRANK: benzodiazepines · Alcohol and Drug Foundation: GHB · FDA 2020: benzodiazepine boxed warning · FDA 2019: gabapentinoids and breathing · NHS: alcohol use disorder

    Experience Report Analysis

    Erowid
    72 Reports
    54 Single-substance
    1996–2025 Date Range
    10 With Age Data
    18 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 54 experience reports (54 single-substance Erowid)

    54 Reports
    18 Effects Detected
    7 Positive
    6 Adverse
    5 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Positive Effects 7

    Euphoria 20.4% (95% interval 12 to 33 percent) 70%
    Music Enhancement 13.0% (95% interval 6 to 24 percent) 70%
    Color Enhancement 13.0% (95% interval 6 to 24 percent) 70%
    Introspection 11.1% (95% interval 5 to 22 percent) 70%
    Empathy 9.3% (95% interval 4 to 20 percent) 70%
    Stimulation 7.4% (95% interval 3 to 18 percent) 70%
    Tactile Enhancement 5.6% (95% interval 2 to 15 percent) 70%

    Adverse Effects 6

    Anxiety 37.0% (95% interval 25 to 50 percent) 70%
    Confusion 20.4% (95% interval 12 to 33 percent) 70%
    Motor Impairment 9.3% (95% interval 4 to 20 percent) 70%
    Memory Suppression 9.3% (95% interval 4 to 20 percent) 70%
    Nausea 7.4% (95% interval 3 to 18 percent) 70%
    Headache 5.6% (95% interval 2 to 15 percent) 70%
    Show 5 neutral or unclassified mentions
    Auditory Effects 29.6% (95% interval 19 to 43 percent)
    Visual Distortions 16.7% (95% interval 9 to 29 percent)
    Dissociation 14.8% (95% interval 8 to 27 percent)
    Time Distortion 11.1% (95% interval 5 to 22 percent)
    Open-Eye Visuals 11.1% (95% interval 5 to 22 percent)

    Common Combinations

    Most co-occurring substances, as a share of all 72 reports filed under Ether; whiskers are 95% intervals

    Form / Preparation

    Most common forms and preparations, as a share of the 44 reports that give one; whiskers are 95% intervals

    Redose Patterns

    Redosing behavior across 49 reports

    4.1% (95% interval 1 to 14 percent) Redosed
    1.0 Avg Doses
    ← Back to Ether